Nitro Mist Spray

SECTION 2: Hazards identification

OSHA Regulatory Status Emergency Overview Physical State: Oily liquid Color: Colorless to yellowish Odor: Odorless DANGER! Flammable liquid and vapor. Harmful if inhaled or absorbed through skin. May be harmful if swallowed in amounts greater than indicated. Causes central nervous system effects. Causes eye irritation. For oral use only.

Potential health effects

Inhalation: Harmful if inhaled. Inhalation of high concentrations may cause central nervous system effects. Exposure may cause a change in heart rate, burning or tingling sensation, dizziness, headache and lightheadedness. Eye Contact: Causes eye irritation. Exposure may cause redness, tearing and irritation. Skin Contact: Harmful if absorbed through skin. May cause allergic or sensitivity reaction in some individuals. Exposure may cause redness, inflammation, lightheadedness and dizziness. Ingestion: May be harmful if swallowed in amounts greater than indicated. Ingestion may cause central nervous system effects. Exposure may cause a change in heart rate, burning or tingling sensation, dizziness, headache and lightheadedness. Overdosage: The manifestations of nitroglycerin overdosage are an extension of its pharmacological actions. Symptoms may include changes in heart rate, changes in vision, confusion, dizziness, flushing, nausea, persistent, throbbing headache, sweating, vomiting and weakness. Contraindications: Hypersensitivity to any of the components in the formulation. Adverse side effects will worsen if medication is taken with alcohol causing severe hypotension.

Potential chronic health

Hypersensitivity to any of the components in the formulation. Long- term chronic effects may include severe headache, hallucinations and skin rash. Pregnancy Category Nitroglycerin Category C. Data on the use of nitroglycerin during human pregnancy is limited. While it has been used safely and effectively to treat maternal hypertension and angina, it has also caused maternal hypotension, with subsequent fetal heart rate changes, including bradycardia and late decelerations, after intravenous administration for these conditions and when used to decrease the risk of hypertension associated with intubation. Some experts are very cautious of the possibility of nitroglycerin-induced hypotension, which may result in decreased uteroplacental perfusion and fetal hypoxemia. Hypotension appears to be less likely if the mother's intravascular volume is replete before nitroglycerin administration. The Collaborative Perinatal Project recorded seven first trimester exposures to nitroglycerin and amyl nitrite and eight patients on other vasodilators. Four malformed infants resulted from this group, although it is not clear whether the mothers of the affected babies had taken nitroglycerin. Data from the Michigan Medicaid Birth Defects Study failed to reveal an association between the use of nitroglycerin and congenital abnormalities (written communication, Franz Rosa, MD, Food and Drug Administration). This was a retrospective study of 229,101 completed pregnancies between 1985 to 1992, of which 50 were exposed to nitroglycerin at some time during the first trimester and 102 were exposed to the drug at any time during pregnancy. Of these pregnancies, one birth defect was observed. This observation did not achieve statistical significance. There were no observations of cardiovascular defects, cleft palate, spina bifida, polydactyly, limb reduction, or hypospadias. These data do not support an association between nitroglycerin and birth defects, although conclusions have not been made based on the small number of pregnancies with known exposure to the drug. Target Organ(s): Cardiovascular system; Central nervous system; Eyes; Skin